trending Market Intelligence /marketintelligence/en/news-insights/trending/SBXXOP0CElfYsPdoYFnyOg2 content esgSubNav
In This List

2A Pharma secures technology to develop vaccine treatments

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


2A Pharma secures technology to develop vaccine treatments

Swedish biotech 2A Pharma AB secured a license to use Medigene AG's AAVLP technology to develop vaccine treatments.

The preclinical stage, adeno-associated virus-like particles technology is believed to have the potential to develop vaccines for cancer and infectious diseases.

The technology is unrelated to Medigene's current immunotherapy programs and was a former research project at the company before it focused on T-cell immunotherapy.

Medigene will receive undisclosed milestone payments as well as royalties on sales of future AAVLP products as a result of the agreement.